Table of Content

1. Overview

1.1 Dravet Syndrome


2. Global Dravet Syndrome Drug Market

2.1 ZX008 Sales Value Forecast
2.2 Epidiolex Sales Value Forecast


3. Regional Dravet Syndrome Drug Market

3.1 The U.S.
3.1.1 The U.S. Dravet Syndrome Patient Volume Forecast
3.1.2 ZX008 Sales Value Forecast in the U.S. Dravet Syndrome Market
3.1.3 Treated Dravet Syndrome Patients with ZX008 in the U.S. Forecast
3.1.4 ZX008 Penetration Forecast in the U.S. Dravet Syndrome Market
3.1.5 Epidiolex Sales Value Forecast in the U.S. Dravet Syndrome Market
3.1.6 Treated Dravet Syndrome Patients with Epidiolex in the U.S. Forecast
3.1.7 Epidiolex Penetration Forecast in the U.S. Dravet Syndrome Market

3.2 Europe
3.2.1 Europe Dravet Syndrome Patient Volume Forecast
3.2.2 ZX008 Sales Value Forecast in Europe Dravet Syndrome Market
3.2.3 Treated Dravet Syndrome Patients with ZX008 in Europe Forecast
3.2.4 ZX008 Penetration Forecast in Europe Dravet Syndrome Market
3.2.5 Epidiolex Sales Value Forecast in Europe Dravet Syndrome Market
3.2.6 Treated Dravet Syndrome Patients with Epidiolex in Europe Forecast
3.2.7 Epidiolex Penetration Forecast in Europe Dravet Syndrome Market


4. Market Dynamics

4.1 Growth Drivers
4.1.1 Attractive Orphan Drug Policies
4.1.2 Rising Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Rising Strategic Alliances

4.2 Key Trends
4.2.1 Development of New Therapeutics
4.2.2 Approval of Cannabidiol Drugs for Dravet Syndrome

4.3 Challenges
4.3.1 Regulatory Challenges
4.3.2 Associated Risks
4.3.3 Insufficient Disease Information and Research Participants
4.3.4 Rising Competition from Generic Industry


5. Competition

5.1 Global Market
5.1.1 Revenue Comparison of Key Players
5.1.2 Market Cap Comparison of Key Players
5.1.3 Comparison of Epidiolex and ZX008


6. Company Profiles

6.1 Zogenix
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies

6.2 Zynerba
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies

6.3 OPKO
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies

6.4 GW Pharmaceuticals
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies



List of Charts

Global ZX008 Sales Value Forecast (2019-2023)
Global Epidiolex Sales Value Forecast (2019-2023)
The U.S. Dravet Syndrome Patient Volume Forecast (2018-2023)
ZX008 Sales Value Forecast in the U.S. Dravet Syndrome Market (2019-2023)
Treated Dravet Syndrome Patients with ZX008 in the U.S. Forecast (2019-2023)
ZX008 Penetration Forecast in the U.S. Dravet Market (2019-2023)
Epidiolex Sales Value Forecast in the U.S. Dravet Syndrome Market (2019-2023)
Treated Dravet Syndrome Patients with Epidiolex in the U.S. Forecast (2019-2023)
Epidiolex Penetration Forecast in the U.S. Dravet Syndrome Market (2019-2023)
Europe Dravet Syndrome Patient Volume Forecast (2018-2023)
ZX008 Sales Value Forecast in Europe Dravet Syndrome Market (2020-2023)
Treated Dravet Syndrome Patients with ZX008 in Europe Forecast (2020-2023)
ZX008 Penetration Forecast in Europe Dravet Syndrome Market (2020-2023)
Epidiolex Sales Value Forecast in Europe Dravet Syndrome Market (2019-2023)
Treated Dravet Syndrome Patients with Epidiolex in Europe Forecast (2019-2023)
Epidiolex Penetration Forecast in Europe Dravet Syndrome Market (2019-2023)
Global Healthcare Expenditure Per Capita (2014-2018)
Global GDP Per Capita (2014-2018)
Revenue Comparison of Key Players (2017)
Market Cap Comparison of Key Players
Pivotal Phase Data of Epidiolex and ZX008
Zogenix Total Revenue and Net Loss/Income (2013-2017)
Zogenix R&D Expenditure (2015-2017)
Zynerba Revenue & Net Loss (2013-2017)
Zynerba R&D Expenditure (2015-2017)
OPKO Revenue by Segment (2017)
OPKO Revenue and Net Loss (2013-2017)
OPKO R&D Expenditure (2015-2017)
GW Pharmaceuticals Revenue by Segment (2017)
GW Pharmaceuticals Revenue and Loss of the year (2013-2017)

List of Tables



Orphan Drug Policies
Dravet Syndrome Therapeutics Pipeline
Zynerba Product Pipeline